A previously overlooked peptide, designated P3, may play a significant role in the development of Alzheimer’s disease, according to research from the University of California, Santa Cruz. The findings, published in a commentary in the journal ChemBioChem, suggest that P3 forms toxic clumps faster than the more widely studied Amyloid beta (Aβ) and could contribute to the disease’s progression.
For decades, Alzheimer’s research has overwhelmingly focused on Aβ, driven by its association with the characteristic brain deposits seen in patients. Billions of dollars have been invested in developing drugs targeting Aβ, yet clinical trials have largely failed to deliver effective treatments, often yielding modest results accompanied by serious side effects like bleeding and stroke.
Jevgenij Raskatov, a biochemist at UC Santa Cruz, argues that the prevailing focus on Aβ may have obscured the potential contribution of P3. “The P3 peptide is, most likely, not the innocent bystander it was commonly thought to be,” Raskatov stated. “There’s still more research to be done. But this could turn Alzheimer’s research on its head.”
Raskatov’s research, along with studies by others, demonstrates that P3 readily forms oligomers and fibrils – structures associated with neurotoxicity. P3 may interact with Aβ, influencing its accumulation and toxicity. A paper published in PubMed, authored by Raskatov, explicitly calls for a revision of the amyloid cascade hypothesis to include P3/Amyloid alpha (Aα).
Previous assumptions held that P3 was harmless and water-soluble, dissolving without causing damage. Raskatov challenged this assumption, initiating a five-year investigation that revealed P3’s capacity to form damaging deposits in the brain, potentially even more rapidly than Aβ.
David Teplow, a colleague at the University of California, Los Angeles, emphasized the need for a reorientation in Alzheimer’s research. “This reevaluation has far-reaching consequences both for basic research and clinical research into the causes and treatment of Alzheimer’s disease,” Teplow said.
The discovery of P3’s potential role comes as over 400 clinical trials targeting Alzheimer’s have largely failed to produce effective therapies. The findings suggest a need to broaden the scope of investigation beyond Aβ and consider the contribution of this previously neglected peptide.